Table 1.
Characteristics of mupirocin-resistant MRSA ST239 isolates (n = 16) in this study
| Characteristic | Description |
|---|---|
| Clinical manifestations | Skin and soft tissue infections: wound infection (n = 6), carbuncle (n = 3), furuncle (n = 3), impetigo (n = 2), and cellulitis (n = 2) |
| Patient age and category | All ages, inpatients (HAMRSA) |
| Antibiotic resistance profile | Sensitive to vancomycin, fusidic acid, and linezolid; resistant to amikacin, cotrimoxazole, erythromycin, mupirocin, netilmicin, ofloxacin, oxacillin, rifampin, and tetracycline; erythromycin induced clindamycin resistance (iMLSB); oxacillin MIC, 256 mg/liter; mupirocin MIC, ≥512 mg/litera |
| Virulence gene profile | Enterotoxins: sea and sek; hemolysins: hla, hld, and hlg; leucocidins: none; innate immune evasions: chp, scn, and sak |
| Resistant determinants | mecA; SCCmec type III (HAMRSA); ileS2a (mupA) gene, mupirocin-resistant gene; ermA, erythromycin resistance and inducible clindamycin resistance |
| Molecular typing | Accessory gene regulator (agr), type I; spa type, t037; MLST, ST239 |
a
High-level mupirocin resistance.